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The SARS-CoV-2 pandemic is causing the scientific com-
munity to look for the best treatment to fight the virus. Studies 
are being carried out worldwide with this purpose looking into 
antiviral drugs, antibiotics, antimalarials, and anticoagulants. 
All these investigations are in their early stages due to the na-
ture of the pandemic, which has spread very rapidly since the 
first case was reported on 17 November, 2019 [1]. This means 
that there are no studies available that could give evidence of 
the most appropriate treatment for SARS-CoV-2. 
Although authors such as Rodón et al. have indicated 
a cytotoxic effect on Vero E6 cells exposed to a fixed con-
centration of SARS-CoV-2 in the presence of decreasing 
concentrations of amantadine [2], Rejdak et al. described 
a series of 22 neurological patients treated with amantadi-
ne: all the patients were tested after reported person-to-
-person contact with SARS-CoV-2 infected subjects, and 
had viral infection confirmed with a real-time reverse 
transcription polymerase chain reaction test for the quali-
tative detection of nucleic acid from SARS-CoV-2 in upper 
and lower respiratory specimens. All of them had spent 
two weeks in quarantine since their documented exposure, 
and none developed clinical manifestations of infectious 
disease [3], or Aranda that exposes the hypothesis that 
amantadine blocks the viroporine channel of COVID-19, 
preventing the release of the viral nucleus into the cell 
cytoplasm [4] and Tipton repurposing other medications, 
especially those with known antiviral properties such as 
amantadine and memantine. 
These medications are inexpensive, widely used, and 
have well-known side effect profiles that are relatively mild 
compared to other potential COVID-19 treatments such as 
hydroxychloroquine [5]. 
The reason for this letter to the editors is to present the case 
of a 75-year-old woman, with Parkinson’s Disease of 16 years’ 
duration, treated with opicapone, 50 mg/day (Ongentys •), pra-
mipexol, 2.1 mg/day (Mirapexin •), levodopa, 1,000 mg/day, 
benserazide, 250 mg/day (Madopar •) and amantadine, 
100 mg/day, with a history of hyperthyroidism treated with 
levothyroxine, 25 mg/day (Euthyrox •), and stomach cancer 
five years ago treated with surgery (Billroth II gastrectomy) 
and pre- and post-surgical chemotherapy, now well controlled 
with no cancer recurrence. 
The husband of this patient, after seven days with 
fever with an unusual sporadic cough, was diagnosed by 
a positive COVID-19 PCR test with bilateral pneumonia 
that was the reason for hospital admission and resulted 
in his death. 
The patient, 45 days after her husband’s death, had not had 
any symptoms related to COVID-19, without fever, cough or 
anosmia, and was being looked after at home by her family. 
Remaining isolated without going outdoors and maintaining 
only contact with their direct caregivers, both had negative 
COVID-19 PCR tests. 
Having seen the previously cited articles which hypothe-
sise that amantadine may have a protective effect against the 
coronavirus [6, 7], this patient has been taking amantadine 
for seven months. 
Is it possible that she was not infected with the coronavirus 
despite having lived with her husband with COVID-19 symp-
toms for seven days, even sharing a bed, with the exposure to 
coughing and aerosols that this produces? May amantadine 
work by inhibiting coronavirus infection? 
For this reason, it is advisable, as the authors recom-
mend [4, 5], that more studies be carried out with patients 
with Parkinson’s Disease who are on amantadine treatment 
and have been directly exposed to SARS-CoV-2, in order 
to demonstrate the hypothesis that they put forward, and 
which I second.
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